Published online Nov 27, 2026. doi: 10.4254/wjh.124439
Revised: August 25, 2026
Accepted: November 5, 2026
Published online: November 27, 2026
Processing time: 158 Days and 0.5 Hours
The hepatic steatosis index (HSI) and fibrosis-4 index (FIB-4) are readily calcu
To evaluate associations between FIB-4 and mortality across HSI categories and assess the incremental predictive value of both indices.
This retrospective cohort study included adults aged ≥ 45 years who participated in the 1999-2018 National Health and Nutrition Examination Survey, with mor
Among 27197 participants (6654 deaths), the fully adjusted complete-case model included 21695 participants (5079 deaths), excluding 5502 participants with missing covariate data. Fully adjusted hazard ratios for elevated vs low FIB-4 were 1.132 (95%CI: 0.931-1.376), 1.350 (1.223-1.491), and 1.173 (1.063-1.295) in the HSI < 30, 30-36, and > 36 groups, respectively. The overall interaction was not statistically significant (P = 0.098). Both indices showed nonlinear associations with mortality. Period-specific estimates were not statistically significant beyond 10 years of follow-up, and effect modification was not consistent over time. The pooled interaction remained statistically nonsignificant after multiple imputation (P = 0.056). Adding both indices to the base clinical model increased Harrell’s C-index by 0.00319 (95%CI: 0.00190-0.00447), whereas adding their interaction provided no further improvement.
Elevated FIB-4 was associated with mortality in HSI 30-36 and > 36, but not significantly in HSI < 30; the overall interaction was nonsignificant, and predictive improvement did not establish clinical utility.
Core Tip: Elevated fibrosis-4 index (FIB-4) was associated with higher all-cause mortality within the hepatic steatosis index (HSI) 30-36 and > 36 categories, but the overall interaction was not statistically significant. The observed gains in predictive performance were statistically detectable but small and do not establish clinical utility. Because HSI and FIB-4 share aminotransferase components and FIB-4 is influenced by age and platelet count, elevated FIB-4 should be interpreted as a composite risk marker rather than direct evidence of advanced liver fibrosis.